The overall market for primary axillary hyperhidrosis is valued at 1.6b and if I am not mistaken there are already few players on the market?
I was very surprised to see the company raising funds to support the launch and didn't go the partnering way. Anyone know why?
Given the company has next to zero experience launching any drug and how expensive it is to set up an internal team, this is not the best way to go about it in my view.
I think the uptake is likely to be much slower than what people here expecting it to be....
Given the market size and competition, I think the approval is already factored in the SP.
BOT - Anything but charting, page-8969
-
- There are more pages in this discussion • 2,462 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.010(2.82%) |
Mkt cap ! $627.0M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.3¢ | 34.5¢ | $582.2K | 1.679M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 32454 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 210000 | 3 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |